Actively Recruiting

Phase 4
Age: 18Years - 70Years
All Genders
NCT04790305

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Led by Fudan University · Updated on 2024-06-27

1072

Participants Needed

34

Research Sites

371 weeks

Total Duration

On this page

Sponsors

F

Fudan University

Lead Sponsor

L

LinkDoc Technology (Beijing) Co. Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a prospective, multicenter, randomized, parallel controlled, open-label study. The primary purpose of this study is to evaluate the efficacy of Huaier Granule on postoperative adjuvant therapy of high-risk early-stage triple-negative invasive ductal carcinoma. The Secondary purposes are to evaluate the safety of long-term use of Huaier granules as postoperative adjuvant treatment of high-risk early-stage triple-negative invasive ductal carcinoma, and the changes of quality of life score after treatment with Huaier granule.

CONDITIONS

Official Title

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged from 18 to 70.
  • Histologically confirmed as breast invasive ductal carcinoma.
  • Molecular typing of breast lesions is triple-negative breast cancer; if multicentric lesions, all must be triple-negative.
  • Regional lymph node metastasis confirmed by postoperative pathology, excluding isolated tumor cells.
  • Residual invasive cancer or axillary lymph node metastasis after completing at least four cycles of neoadjuvant chemotherapy.
  • No local recurrence or distant metastasis of the tumor.
  • Randomization during postoperative adjuvant therapy or within 60 days after its completion.
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
  • Hepatic and renal function within specified laboratory limits.
  • Adequate blood counts: neutrophils ≥ 1.5×10⁹/L, platelets ≥ 100×10⁹/L, hemoglobin ≥ 90 g/L without transfusion.
  • Voluntary participation with good compliance and signed informed consent form.
Not Eligible

You will not qualify if you...

  • Bilateral breast cancer.
  • Severe heart, liver, kidney, or endocrine diseases posing safety risks or affecting compliance.
  • Other malignant tumors within the past 5 years, except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix.
  • Allergy to Huaier granule.
  • Pregnant, lactating, or planning pregnancy during the study.
  • Participation in other clinical trials within the last 3 months.
  • Poor compliance or other reasons deemed inappropriate by researchers.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 34 locations

1

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

Actively Recruiting

2

The First Affiliated Hospital of USTC, Anhui Provincial Hospital

Hefei, Anhui, China

Actively Recruiting

3

Cancer Hospital Chinese Academy of Medical Science

Beijing, Beijing Municipality, China

Actively Recruiting

4

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Actively Recruiting

5

Fujian Cancer Hospital

Fuzhou, Fujian, China

Actively Recruiting

6

Guangdong Provincial Hospital of Traditional Chinese Medicine

Guangzhou, Guangdong, China

Actively Recruiting

7

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Actively Recruiting

8

The Fourth Hospital of Hebei Medical University, Hebei Tumor Hospital

Shijiazhuang, Hebei, China

Actively Recruiting

9

The First Affiliates Hospital of Ha'erbin University

Harbin, Heilongjiang, China

Actively Recruiting

10

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Actively Recruiting

11

Hubei Cancer Hospital

Wuhan, Hubei, China

Actively Recruiting

12

Renmin Hospital of Wuhan University

Wuhan, Hubei, China

Actively Recruiting

13

Tongji Medical College of HUST

Wuhan, Hubei, China

Actively Recruiting

14

Union Hospital Tongji Medical College Huazhong Univeristy of Science and Technology

Wuhan, Hubei, China

Actively Recruiting

15

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China

Actively Recruiting

16

Hunan Cancer Hospital

Changsha, Hunan, China

Actively Recruiting

17

The Second Xiangya Hospital of Central South University

Changsha, Hunan, China

Actively Recruiting

18

Jiangsu Province Hospital of Chinese Medicine

Nanjing, Jiangsu, China

Actively Recruiting

19

Jiangsu Provincial Hospital

Nanjing, Jiangsu, China

Actively Recruiting

20

Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

Nanjing, Jiangsu, China

Actively Recruiting

21

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Actively Recruiting

22

Northern Jiangsu People's Hospital

Yangzhou, Jiangsu, China

Actively Recruiting

23

The Second Hospital of Jilin University

Changchun, Jilin, China

Actively Recruiting

24

Liaoning Cancer Hospital & Institute

Shenyang, Liaoning, China

Actively Recruiting

25

Qilu Hospital of Shandong University

Jinan, Shandong, China

Actively Recruiting

26

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

Actively Recruiting

27

LongHua Hospital Shanghai University of Traditional Chinese Medicine

Shanghai, Shanghai Municipality, China

Actively Recruiting

28

The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)

Xi’an, Shanxi, China

Actively Recruiting

29

The First Affiliatied Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Actively Recruiting

30

The Second Affiliated Hospital Zhejiang Univerisity of Medicine

Hangzhou, Zhejiang, China

Actively Recruiting

31

Huamei Hospital, University of Chinese Academy of Sciences

Ningbo, Zhejiang, China

Actively Recruiting

32

Ningbo Medical Center Lihuili Hospital

Ningbo, Zhejiang, China

Actively Recruiting

33

The First School of Medicine, School of Information and Engineering,the First Affiliated Hospital of WMU

Wenzhou, Zhejiang, China

Actively Recruiting

34

Fudan University Shanghai Cancer Center

Shanghai, China, 200032

Actively Recruiting

Loading map...

Research Team

Z

Zhimin Shao, PhD

CONTACT

L

Liang Huang, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | DecenTrialz